Efficacy Transverse Abdominal Plane (TAP) Block Renal Transplant Surgery

Efficacy of Ultrasound-guided Transverse Abdominal Plane Block for Analgesia in Renal Transplantation

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03181438

Enrollment

Registered

2017-06-08

Start date

2017-06-03

Completion date

2017-09-30

Last updated

2017-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Insufficiency, Chronic, Acute Pain, Kidney Transplantation, Anesthesia, Conduction

Keywords

Renal Transplantation, Acute pain, Regional Anesthesia, TAP Block

Brief summary

The objective of this study is to evaluate the efficacy and safety of transverse abdominal plane block in patients undergoing renal transplant surgery.Adult renal transplant recipients will be prospectively randomized to receive a standard general anesthetic technique supplemented with ropivacaine 0.375% 20 mL TAP block or sham block with 20 mL 0.9% saline. Both groups will receive patient-controlled morphine analgesia. Patient assessment will occur in the postanesthetic care unit and at 1, 2, 4, 6, 12, and 24 hours. The primary outcome is total morphine consumption in the first 24 hours after renal transplantation. Other outcomes asses include pain scores, presence of nausea or vomiting, excessive sedation, and respiratory depression.

Interventions

PROCEDURETAP Block

It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation

PROCEDURESaline Group

t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* end-stage renal disease undergoing cadaveric renal transplantation

Exclusion criteria

* Contraindications to the use of morphine * Contraindications to the use ropivacaine * Peripheral neuropathy * Inability to use a Patient Control Analgesia device

Design outcomes

Primary

Measure	Time frame	Description
Morphine Consumption	24 hours post-operative	Patient Control Analgesia: morphine sulfate 2 mg IV every 5 minutes until visual analog scale pain score (0 = no pain, 10 = worst possible pain) is 3 or less, and continued at the following settings for a 24-hour period: 1 mg bolus, 7-minute lockout, and 30 mg maximum 4-hourly dose.

Secondary

Measure	Time frame	Description
Pain Score	24 hours post-operative	Visual analogue score (VAS) at rest and movement

Countries

Brazil

Contacts

Primary ContactLeonardo HC Ferraro, Professor

leohcferraro1@hotmail.com+ 55 11 999516103

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026